vs
ADAMAS TRUST, INC.（ADAM）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是ADAMAS TRUST, INC.的1.5倍（$65.1M vs $43.2M），ADAMAS TRUST, INC.净利率更高（124.0% vs 5.6%，领先118.4%），ADAMAS TRUST, INC.同比增速更快（61.6% vs 3.6%），ADAMAS TRUST, INC.自由现金流更多（$125.9M vs $18.0M），过去两年ADAMAS TRUST, INC.的营收复合增速更高（55.5% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
ADAM vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.5倍
$43.2M
营收增速更快
ADAM
高出58.0%
3.6%
净利率更高
ADAM
高出118.4%
5.6%
自由现金流更多
ADAM
多$107.9M
$18.0M
两年增速更快
ADAM
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $43.2M | $65.1M |
| 净利润 | $53.5M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | — | 12.2% |
| 净利率 | 124.0% | 5.6% |
| 营收同比 | 61.6% | 3.6% |
| 净利润同比 | 270.5% | 316.6% |
| 每股收益（稀释后） | $0.45 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADAMMLAB
| Q4 25 | $43.2M | $65.1M | ||
| Q3 25 | $36.6M | $60.7M | ||
| Q2 25 | $36.4M | $59.5M | ||
| Q1 25 | $33.1M | $62.1M | ||
| Q4 24 | $26.7M | $62.8M | ||
| Q3 24 | $20.2M | $57.8M | ||
| Q2 24 | $19.0M | $58.2M | ||
| Q1 24 | $17.9M | $58.9M |
净利润ADAMMLAB
| Q4 25 | $53.5M | $3.6M | ||
| Q3 25 | $44.8M | $2.5M | ||
| Q2 25 | $8.5M | $4.7M | ||
| Q1 25 | $42.2M | $-7.1M | ||
| Q4 24 | $-31.4M | $-1.7M | ||
| Q3 24 | $42.8M | $3.4M | ||
| Q2 24 | $-15.6M | $3.4M | ||
| Q1 24 | $-57.9M | $-254.6M |
毛利率ADAMMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
营业利润率ADAMMLAB
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | 7.8% | ||
| Q2 25 | 11.7% | 5.1% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | -119.0% | 9.2% | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | -124.7% | 9.6% | ||
| Q1 24 | -448.8% | -460.6% |
净利率ADAMMLAB
| Q4 25 | 124.0% | 5.6% | ||
| Q3 25 | 122.5% | 4.1% | ||
| Q2 25 | 23.4% | 8.0% | ||
| Q1 25 | 127.4% | -11.4% | ||
| Q4 24 | -117.5% | -2.7% | ||
| Q3 24 | 211.7% | 5.9% | ||
| Q2 24 | -81.9% | 5.8% | ||
| Q1 24 | -324.1% | -432.2% |
每股收益（稀释后）ADAMMLAB
| Q4 25 | $0.45 | $0.65 | ||
| Q3 25 | $0.36 | $0.45 | ||
| Q2 25 | $-0.04 | $0.85 | ||
| Q1 25 | $0.33 | $-1.30 | ||
| Q4 24 | $-0.46 | $-0.31 | ||
| Q3 24 | $0.36 | $0.63 | ||
| Q2 24 | $-0.29 | $0.62 | ||
| Q1 24 | $-0.75 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $210.3M | $29.0M |
| 总债务越低越好 | $735.8M | $68.4M |
| 股东权益账面价值 | $1.4B | $186.7M |
| 总资产 | $12.6B | $434.8M |
| 负债/权益比越低杠杆越低 | 0.52× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资ADAMMLAB
| Q4 25 | $210.3M | $29.0M | ||
| Q3 25 | $185.3M | $20.4M | ||
| Q2 25 | $160.4M | $21.3M | ||
| Q1 25 | $177.1M | $27.3M | ||
| Q4 24 | $167.4M | $27.3M | ||
| Q3 24 | $195.1M | $24.3M | ||
| Q2 24 | $235.5M | $28.5M | ||
| Q1 24 | $226.9M | $28.2M |
总债务ADAMMLAB
| Q4 25 | $735.8M | $68.4M | ||
| Q3 25 | $766.6M | $69.4M | ||
| Q2 25 | $653.0M | $70.3M | ||
| Q1 25 | $654.4M | $71.3M | ||
| Q4 24 | $573.2M | $72.2M | ||
| Q3 24 | $699.4M | $73.1M | ||
| Q2 24 | $800.7M | $74.1M | ||
| Q1 24 | $1.0B | — |
股东权益ADAMMLAB
| Q4 25 | $1.4B | $186.7M | ||
| Q3 25 | $1.4B | $178.5M | ||
| Q2 25 | $1.4B | $172.5M | ||
| Q1 25 | $1.4B | $159.8M | ||
| Q4 24 | $1.4B | $155.2M | ||
| Q3 24 | $1.4B | $161.5M | ||
| Q2 24 | $1.4B | $150.7M | ||
| Q1 24 | $1.5B | $145.4M |
总资产ADAMMLAB
| Q4 25 | $12.6B | $434.8M | ||
| Q3 25 | $12.4B | $430.4M | ||
| Q2 25 | $10.6B | $435.7M | ||
| Q1 25 | $10.0B | $433.3M | ||
| Q4 24 | $9.2B | $433.3M | ||
| Q3 24 | $8.9B | $454.1M | ||
| Q2 24 | $8.2B | $440.4M | ||
| Q1 24 | $7.4B | $446.8M |
负债/权益比ADAMMLAB
| Q4 25 | 0.52× | 0.37× | ||
| Q3 25 | 0.55× | 0.39× | ||
| Q2 25 | 0.47× | 0.41× | ||
| Q1 25 | 0.47× | 0.45× | ||
| Q4 24 | 0.41× | 0.47× | ||
| Q3 24 | 0.48× | 0.45× | ||
| Q2 24 | 0.56× | 0.49× | ||
| Q1 24 | 0.67× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.0M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $125.9M | $18.0M |
| 自由现金流率自由现金流/营收 | 291.6% | 27.7% |
| 资本支出强度资本支出/营收 | 18.9% | 1.1% |
| 现金转化率经营现金流/净利润 | 2.50× | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流ADAMMLAB
| Q4 25 | $134.0M | $18.8M | ||
| Q3 25 | $6.9M | $8.2M | ||
| Q2 25 | $39.2M | $1.9M | ||
| Q1 25 | $25.8M | $12.7M | ||
| Q4 24 | $14.1M | $18.1M | ||
| Q3 24 | $-922.0K | $5.3M | ||
| Q2 24 | $-993.0K | $10.7M | ||
| Q1 24 | $-13.1M | $12.9M |
自由现金流ADAMMLAB
| Q4 25 | $125.9M | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | $-10.6M | $17.3M | ||
| Q3 24 | $-8.6M | $3.5M | ||
| Q2 24 | $-8.6M | $9.9M | ||
| Q1 24 | $-19.1M | $12.3M |
自由现金流率ADAMMLAB
| Q4 25 | 291.6% | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | -39.6% | 27.6% | ||
| Q3 24 | -42.3% | 6.0% | ||
| Q2 24 | -44.9% | 16.9% | ||
| Q1 24 | -107.0% | 21.0% |
资本支出强度ADAMMLAB
| Q4 25 | 18.9% | 1.1% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 92.3% | 1.3% | ||
| Q3 24 | 37.7% | 3.1% | ||
| Q2 24 | 39.7% | 1.5% | ||
| Q1 24 | 33.5% | 0.9% |
现金转化率ADAMMLAB
| Q4 25 | 2.50× | 5.17× | ||
| Q3 25 | 0.15× | 3.32× | ||
| Q2 25 | 4.59× | 0.40× | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.02× | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADAM
| Other | $19.6M | 45% |
| Constructive Loans LLC | $14.4M | 33% |
| Multifamily | $9.1M | 21% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
